Merck KGaA (OTCMKTS:MKGAY) Receives Average Recommendation of “Buy” from Analysts

Shares of Merck KGaA (OTCMKTS:MKGAYGet Rating) have received an average rating of “Buy” from the seven brokerages that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $252.50.

Several brokerages have recently commented on MKGAY. JPMorgan Chase & Co. decreased their price objective on shares of Merck KGaA from €270.00 ($290.32) to €250.00 ($268.82) and set an “overweight” rating on the stock in a research report on Monday, March 14th. UBS Group upgraded shares of Merck KGaA from a “sell” rating to a “neutral” rating in a research report on Monday, February 28th.

Shares of MKGAY stock remained flat at $$38.36 on Monday. Merck KGaA has a fifty-two week low of $32.53 and a fifty-two week high of $42.02. The company’s 50-day moving average price is $38.36.

Merck KGaA Company Profile (Get Rating)

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.

Featured Articles

Analyst Recommendations for Merck KGaA (OTCMKTS:MKGAY)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.